Spearn will also be retiring from the board. The board will commence a search for suitable candidates to take on the CEO position.
“The board thanks Scott for his service and leadership, but we understand his decision to step down,” said von der Porten. “During his tenure as president and CEO, MedX has completed the development of its SIAscopy on DermSecure Telemedicine platform, has entered into major distribution arrangements and has significantly strengthened its balance sheet. We wish him the very best. I am confident that under the direction of MedX’s executive leadership team, the company will enjoy continued success in the future.”
Spearn noted, “It has been a privilege to have led MedX during an important period of transformation and growth. I am proud to have worked with my MedX colleagues who are so committed to the development of the SIAscopy technology and the DermSecure Telemedicine platform that represents such a significant development in the diagnosis process for early detection of melanoma.”